- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03890900
T2DXcel Mobile Application (T2DXcel)
Developing and Evaluating the T2DXcel Mobile Application for Adult Patients With Type 2 Diabetes
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The Bronx has the heaviest burden of diabetes within New York City (NYC) and statewide. The highest diabetes hospitalization and death rates in NYC occur in the Bronx, which has hospitalization rates approximately 25 percent above the statewide average. The Bronx is one of the poorest urban counties in the nation, and diabetes disproportionately impacts high-poverty communities. The borough has an ethnically and racially diverse population (53.5% of residents are Hispanic and 36.5% are black), and diabetes is highly prevalent among blacks and Hispanics. Obesity, a major risk factor for diabetes, is also prevalent with nearly 33% (much higher than the 24% prevalence of obesity in NYC) of Bronx adults being obese. Among the many social determinants of health, medical provider practice behaviors, suboptimal access to health care, lack of patient knowledge regarding proper medication administration and potential side effects, and difficulty adhering to medical regimens by patients and families all contribute to poor diabetes outcomes.
With appropriate medical care including education (especially regarding potentially modifiable lifestyle factors that contribute to diabetes), well-informed patients can achieve diabetes control. However, there are significant challenges in providing effective patient education in the ambulatory setting, such as time constraints and prioritizing other issues (e.g. comorbid conditions) above comprehensive diabetes education. While patient education and teaching self-management skills are critical to improve diabetes outcomes, such strategies will succeed only as part of more comprehensive interventions. Diabetes self-management education (DSME) has been linked to decreases in hemoglobin A1c, reductions in the onset and/or progression of diabetes complications, reductions in diabetes-related hospitalizations and readmissions, and improvements in quality of life, lifestyle behaviors (e.g. physical activity, healthier eating), self-efficacy, and coping skills. The American Association of Diabetes Educators (AADE) has described the AADE7 Self-Care Behaviors (healthy eating, being active, monitoring, taking medications, problem solving, healthy coping, reducing risks) as a framework to organize and structure patient-centered education. Despite the proven benefits of DSME, less than 10% of type 2 diabetes (T2D) patients receive structured education for a variety of reasons: providers' misunderstanding of DSME effectiveness and confusion about how to make referrals; many clinic sites' lack of access to DSME services; and some payers' lack of coverage for DSME services. With the increasing use of smartphones and the internet, health information technology (IT)-based approaches (e.g. mobile applications, text messaging platforms, internet-based educational modules, and telemedicine/telehealth interventions) - through standalone interventions or by supplementing education (i.e. by reinforcing content delivered in-person) - can increase patients' access to DSME, and have been linked to improvements in hemoglobin A1c and other outcomes. Mobile applications ('apps') can provide day-to-day support for patients with diabetes, but commonly lack evidence-based content and/or comprehensiveness. A recent study reported that only a small percentage of the diabetes apps available on the iOS and Android stores supported the AADE7 behaviors regarding problem solving, healthy coping, and reducing risks. Another recent article suggested that few apps provided personalized education or tailored therapeutic support. As with other chronic conditions, diabetes mobile applications are often characterized by low retention rates and decreased user engagement with the app following the initial download.
Given the need for personalizable and adaptive mobile applications for patients with type 2 diabetes, this proposal will develop, evaluate, and refine a patient-centered mobile application (T2DXcel), which will deliver tailored and algorithm-based diabetes education to improve process and diabetes-related outcomes.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New York
-
Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
English-speaking individuals >18 years with:
- T2D (diagnosis made by a healthcare provider) on an anti-diabetic medication with hemoglobin A1c > 6.5% at the time of recruitment and enrollment
- Diabetes care at Montefiore
- Able to give informed consent; and d) smartphone (iOS or Android) access
Exclusion Criteria:
- Pregnancy
- Chronic illness with organ failure (heart failure, severe liver disease, chronic kidney disease stage 3-4 or dialysis) or requiring chemotherapy or steroid use
- Severe psychiatric or cognitive problems that would prohibit an individual from completing the protocol
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Otro: T2DXcel mobile application
T2DXcel is a mobile application (patient-facing) that delivers guideline-based diabetes education.
|
T2DXcel is a mobile application (patient-facing) that delivers guideline-based diabetes education.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline hemoglobin A1c to 3 and 6 months
Periodo de tiempo: Baseline, 3 months, 6 months
|
Patients' glycemic control measured by hemoglobin A1c
|
Baseline, 3 months, 6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Patient satisfaction measured by the Client Satisfaction Questionnaire-8
Periodo de tiempo: Baseline, 3 months, 6 months
|
Patient satisfaction measured by the Client Satisfaction Questionnaire-8
|
Baseline, 3 months, 6 months
|
|
Change from baseline diabetes knowledge to 3 months and 6 months
Periodo de tiempo: Baseline, 3 months, 6 months
|
Diabetes knowledge as measured by the validated Diabetes Knowledge Questionnaire-24
|
Baseline, 3 months, 6 months
|
|
Change from baseline diabetes self-management capabilities to 3 months and 6 months
Periodo de tiempo: Baseline, 3 months, 6 months
|
Diabetes self-management capabilities as measured by the Diabetes Self-Management Questionnaire
|
Baseline, 3 months, 6 months
|
|
Change from baseline diabetes self-efficacy to 3 months and 6 months
Periodo de tiempo: Baseline, 3 months, 6 months
|
Diabetes self-efficacy as measured by the Diabetes Empowerment Scale-Short Form
|
Baseline, 3 months, 6 months
|
|
Change from baseline diabetes quality of life to 3 months and 6 months
Periodo de tiempo: Baseline, 3 months, 6 months
|
Patients' diabetes quality of life measured by the Diabetes Quality of Life questionnaire
|
Baseline, 3 months, 6 months
|
|
Change from baseline LDL cholesterol to 3 months and 6 months
Periodo de tiempo: Baseline, 3 months, 6 months
|
LDL cholesterol
|
Baseline, 3 months, 6 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Sunit Jariwala, MD, Albert Einstein College of Medicine and Montefiore Medical Center
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2018-9590
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .